Abstract
Intracerebral hemorrhage (ICH), which accounts for 10% of all strokes, leads to higher morbidity and mortality compared with other stroke subtypes. Hypertension has been recognized as a major risk factor for ICH. Current antihypertensive options have not been fully effective for either prevention of ICH or ameliorating its complications. Therefore, attempts should be made to use novel antihypertensive medications for more effective management of blood pressure (BP) in the acute phase of ICH. Imidazoline receptor (IR) agonists can potentially be effective agents for BP control with the adjunctive ability to attenuate post-ICH brain injury. IR agonists render neuroprotective effects including inhibition of inflammatory reactions, apoptotic cell death, excitotoxicity, and brain edema. Given these properties, the present review aims to focus on the application of IR agonists for managing BP in ICH patients.
Keywords: Intracerebral haemorrhage, hypertension, imidazoline receptors, inflammation, excitotoxicity, apoptosis.
Current Molecular Medicine
Title:Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Volume: 18 Issue: 4
Author(s): J. Mahmoudi, A. Majdi, S. Lattanzi, M. Di Napoli, E.M. Bershad, C.M.P. Rodrigues and A.A. Divani*
Affiliation:
- Department of Neurology, University of Minnesota, Minneapolis, MN,United States
Keywords: Intracerebral haemorrhage, hypertension, imidazoline receptors, inflammation, excitotoxicity, apoptosis.
Abstract: Intracerebral hemorrhage (ICH), which accounts for 10% of all strokes, leads to higher morbidity and mortality compared with other stroke subtypes. Hypertension has been recognized as a major risk factor for ICH. Current antihypertensive options have not been fully effective for either prevention of ICH or ameliorating its complications. Therefore, attempts should be made to use novel antihypertensive medications for more effective management of blood pressure (BP) in the acute phase of ICH. Imidazoline receptor (IR) agonists can potentially be effective agents for BP control with the adjunctive ability to attenuate post-ICH brain injury. IR agonists render neuroprotective effects including inhibition of inflammatory reactions, apoptotic cell death, excitotoxicity, and brain edema. Given these properties, the present review aims to focus on the application of IR agonists for managing BP in ICH patients.
Export Options
About this article
Cite this article as:
Mahmoudi J. , Majdi A. , Lattanzi S. , Di Napoli M. , Bershad E.M. , Rodrigues C.M.P. and Divani A.A.*, Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage, Current Molecular Medicine 2018; 18 (4) . https://dx.doi.org/10.2174/1566524018666180926163712
DOI https://dx.doi.org/10.2174/1566524018666180926163712 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adrenergic and V1-ergic Agonists/Antagonists Affecting Recovery from Brain Trauma in the Lund Project Act on Astrocytes
Current Signal Transduction Therapy Harnessing the Capacity of Cell-Penetrating Peptides for Drug Delivery to the Central Nervous System
Current Pharmaceutical Biotechnology Inflammation and Inflammatory Cell Recruitment in Acute Cerebrovascular Diseases
Current Immunology Reviews (Discontinued) Bv8-Prokineticins and their Receptors: Modulators of Pain
Current Pharmaceutical Biotechnology Plasma Level of D-dimer is an Independent Diagnostic Biomarker for Deep Venous Thrombosis in Patients with Ischemic Stroke
Current Neurovascular Research HHT: A Rare Disease with A Broad Spectrum of Clinical Aspects
Current Pharmaceutical Design Device-based Therapies for Resistant Hypertension
Current Pharmaceutical Design Melanoma
Current Cancer Therapy Reviews Towards More Successful Gene Therapy Clinical Trials for β-Thalassemia
Current Molecular Medicine The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets Role of Citicoline in Promoting the Repair of Acute Peripheral Nerve Injury in Rat Models
Neuroscience and Biomedical Engineering (Discontinued) Curcumin Suppresses Tumor Growth and Angiogenesis in Human Glioma Cells Through Modulation of Vascular Endothelial Growth Factor/ Angiopoietin-2/Thrombospondin-1 Signaling
CNS & Neurological Disorders - Drug Targets Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets TNF α Signaling Beholds Thalidomide Saga: A Review of Mechanistic Role of TNF-α Signaling Under Thalidomide
Current Topics in Medicinal Chemistry Recent Advances in the Medicinal Chemistry of Sodium Channel Blockers and their Therapeutic Potential
Current Topics in Medicinal Chemistry Diffusion Tensor Imaging Parameters in Children with Acute Hyperammonemic Encephalopathy due to Urea Cycle Enzyme Defects and Organic Acidemia
Current Medical Imaging Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Roles of miRNA in Cardiovascular Development and Dysfunction
Current Medicinal Chemistry Editorial: (Thematic Issue) Novel Concepts on the Blood-Brain Barrier and Brain Pathology. New Therapeutic Approaches
CNS & Neurological Disorders - Drug Targets